Fanciulli, ChiaraBerenguer, JuanBusca, CarmenVivancos, María JTéllez, María JDomínguez, LourdesDomingo, PereNavarro, JordiSantos, JesúsIribarren, José AMorano, LuisArtero, ArturoMoreno, JavierRivero-Román, AntonioSantos, IgnacioGiner, LiviaArmiñanzas, CarlosMontero, MartaManzardo, ChristianCifuentes, CarmenGarcía, CoralGalindo, María JFerrero, Oscar LSanz, Joséde la Fuente, BelénRodríguez, CarmenGaspar, GabrielPérez, LauraLosa, Juan EForce, LuisVeloso, SergioMartínez-Alfaro, ElisaJarrín, InmaculadaDe Miguel, MartaGonzález Garcia, JuanGeSIDA 8514 Study Group2023-05-032023-05-032022-01-17http://hdl.handle.net/10668/19960We assessed the prevalence of anti-hepatitis C virus (HCV) antibodies and active HCV infection (HCV-RNA-positive) in people living with HIV (PLWH) in Spain in 2019 and compared the results with those of four similar studies performed during 2015-2018. The study was performed in 41 centres. Sample size was estimated for an accuracy of 1%. Patients were selected by random sampling with proportional allocation. The reference population comprised 41 973 PLWH, and the sample size was 1325. HCV serostatus was known in 1316 PLWH (99.3%), of whom 376 (28.6%) were HCV antibody (Ab)-positive (78.7% were prior injection drug users); 29 were HCV-RNA-positive (2.2%). Of the 29 HCV-RNA-positive PLWH, infection was chronic in 24, it was acute/recent in one, and it was of unknown duration in four. Cirrhosis was present in 71 (5.4%) PLWH overall, three (10.3%) HCV-RNA-positive patients and 68 (23.4%) of those who cleared HCV after anti-HCV therapy (p = 0.04). The prevalence of anti-HCV antibodies decreased steadily from 37.7% in 2015 to 28.6% in 2019 (p  In Spain, the prevalence of active HCV infection among PLWH at the end of 2019 was 2.2%, i.e. 90.0% lower than in 2015. Increased exposure to DAAs was probably the main reason for this sharp reduction. Despite the high coverage of treatment with direct-acting antiviral agents, HCV-related cirrhosis remains significant in this population.enAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/HIV infection/*epidemiologycoinfection/*epidemiologyhepatitis C/drug therapy/*epidemiologyAntiviral AgentsCoinfectionHIV InfectionsHepacivirusHepatitis CHepatitis C, ChronicHumansLiver CirrhosisRNASpainresearch article35037379open access10.1111/hiv.132291468-1293PMC9543728https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/hiv.13229https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543728/pdf